Shannon N. Westin, MD, MPH, FACOG, MD Anderson Cancer Center

Articles

Novel Combinations for the Treatment of Advanced EC

May 19th 2021

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.

Emerging Data From Ongoing IO Combination Trials in EC

May 19th 2021

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Patient Selection for Lenvatinib-Pembrolizumab for Advanced EC

May 12th 2021

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Impact of Lenvatinib-Pembrolizumab on Clinical Practice in Advanced EC

May 12th 2021

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

Safety Results From KEYNOTE-775 Trial in Advanced EC

May 4th 2021

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

Phase 3 KEYNOTE-775 Trial in Advanced Endometrial Cancer

May 4th 2021

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

Upcoming Clinical Trials for Ovarian Cancer

July 20th 2020

Emerging Therapies in Recurrent Ovarian Cancer

July 20th 2020

Antibody Drug Conjugates for Ovarian Cancer

July 20th 2020

Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

July 20th 2020

New Data for Secondary Surgery in Ovarian Cancer

July 20th 2020

PARP Inhibitors in Recurrent Ovarian Cancer

July 20th 2020

Expert Approaches for Treating Recurrent Ovarian Cancer

July 20th 2020

Emerging Combinations in the Frontline Setting of Ovarian Cancer

July 20th 2020

Patient Preference for Treatment in Ovarian Cancer

July 20th 2020

PAOLA-1 Study Surgical Subset for Ovarian Cancer

July 20th 2020

NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

July 20th 2020

Personalized Dosing of Niraparib in Ovarian Cancer

July 20th 2020

Treating Homologous Recombination Proficient Ovarian Cancer

July 20th 2020

Treating BRCA+ Ovarian Cancer

July 20th 2020